Navigation Links
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Date:10/7/2008

efficacy in inflammatory bowel disease targets and look forward to future research to uncover the product's potential in this important therapeutic area."

About the Studies

Results from CLIN 1001-004 were presented at ACG in a poster entitled "Larazotide Acetate Prevents Immunologic Changes Induced by Gluten Challenge in Celiac Disease Patients" (Poster 446). The randomized, double-blind, placebo-controlled study was designed to evaluate the effects of larazotide acetate on the systemic immunologic changes induced by a two week gluten challenge in patients with celiac disease. Study results showed that larazotide acetate was well tolerated and showed signs of efficacy in preventing immunologic changes induced by gluten challenge in patients with celiac disease, consistent with the beneficial effects observed on intestinal permeability, signs and symptoms. Clinical findings included:

-- Gluten challenge in the placebo (control) group resulted in an increase in circulating regulatory T cells (CD4, CD25, FOX-P3+) and a decrease in B cells (CD3, CD19+). These changes were completely prevented in the group on larazotide acetate.

-- There was a small, not statistically significant increase in the anti-tTG titer in the placebo (control) group, which was prevented in the group on larazotide acetate.

-- Other trends in specific monocyte populations induced by gluten challenge were also prevented to varying extents by larazotide acetate.

The second presentation, "Larazotide Acetate, a Tight Junction Inhibitor Peptide, Inhibits Epithelial Permeability Induced by TNF-alpha and IL-4" (Poster 1052) included results from a study investigating the effect of larazotide acetate on tumor necrosis factor (TNF-alpha) and interleukin (IL-4) induced permeability. The study showed that larazotide acetate inhibited increased permeability mediated with TNF-alpha and IL-4, which suggests the potential of larazotide acetate as a therapeutic agent for
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
5. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
6. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Orexigen Therapeutics, Inc. (Nasdaq: ... Cannell has joined as Chief Commercial Officer. ... Contrave® /Mysimba™ (naltrexone HCl / bupropion HCl extended ... global commercial strategy, assuming responsibilities previously held by ... commercial effort through the U.S. launch of Contrave, ...
(Date:3/30/2015)... 2015 NiQ Health, "the ... the high level interface capabilities of their CarePlus™ ... The partnership between CarePlus™ and ClinicAll ... allows patients to choose the most appropriate alarm ... The advanced functionality of CarePlus™ allows patient alarms ...
(Date:3/30/2015)... , March 30, 2015  Edison Nation Medical, ... worldwide search for product innovations to assist seniors ... ideas uncovered during the 8-week search will be ... commercialization.  Invention ideas can be submitted through a ... through May 28, 2015. The objective ...
Breaking Medicine Technology:Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 2Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 3Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 4Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 5Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 6Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 7Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 8Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 9Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 10NiQ Health Announces CarePlus(TM) Integration with ClinicAll 2Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 2Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 3
... BELL, Pa., Aug. 8, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... ended June 30, 2011. Total revenue was $2.4 million ... 2011, compared to $1.1 million and $2.5 million for the same ... and six months ended June 30, 2011, were $7.6 million and ...
... Aug. 5, 2011 Jury selection in the second trial ... begun in Clark County, Nevada. The Nevada Supreme Court lifted ... it was determined by the court that nurse David Hambrick, ... "does not possess the requisite skill, knowledge or experience to ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 9Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 10Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 11Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs 2
(Date:3/30/2015)... On March 11, 2015, Elle Magazine, in an ... six new treatment options for dealing with stubborn, unwanted fat. ... topical product. The other three technologies use devices to deliver ... freezing cold ( CoolSculpting ) to kill fat cells. (see: ... us to permanently remove unwanted fat," says Dr. Simon Ourian, ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 A key ... neurological diseases plays an important role in the response ... scientists from the Icahn School of Medicine at Mount ... diseases have long been associated with inflammation, part of ... when immune cells home in to attack invaders like ...
(Date:3/30/2015)... Vancouver, BC (PRWEB) March 30, 2015 ... recently announced that the majority of cases taken up ... trial. This means that the lawyers help protect the ... through the tedious court process. The announcement comes across ... their primary job is to provide convenience to their ...
(Date:3/30/2015)... Jose, California (PRWEB) March 30, 2015 ... population and government efforts to develop and establish chronic ... management therapies. Growth in the market is poised to ... as a result of the increase in chronic health ... diseases, and rheumatoid arthritis, among others. While conventional treatment ...
(Date:3/30/2015)... March 30, 2015 On March 19th, ... Field, home of the Detroit Lions, LiveToBeSober.org hosted the ... recognized pastors, ministers and bishops as well as other ... the audience at the luncheon, including retired Detroit Lions ... Per Wickstrom and two survivors of their own personal ...
Breaking Medicine News(10 mins):Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 2Health News:Mount Sinai Scientists Establish Link Between Neurodegenerative Disease and the Body’s Response to Viral Infection 3Health News:Jiwa Law Corporation States That Majority of Their Cases Get Settled Before Trial 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2
... researchers has constructed a model that predicts how an ... airliners. ,The study, "Modeling the Worldwide Spread ... in the January issue of the journal PLoS Medicine. ... world's largest-scale epidemic simulation of its kind. ...
... suggests that TEMPE, a topical anesthetic spray has the ... with premature ejaculation and might be useful// as a ... in the February issue of the urology journal BJU ... studied 54 men with premature ejaculation, randomly assigning them ...
... Rs.350 million to provide health insurance to around 1.2 ... H.D. Kumaraswamy announced// here Wednesday. ,"We are aware ... thousands of families. We have decided to provide health ... has been fixed for the project this year," Kumaraswamy ...
... that a novel needle-free vaccine approach// is effective and ... of Alzheimer’s disease. ,The transdermal, or ... of preventing or treating the devastating neurodegenerative disease with ... ,The study was published online this week in The ...
... effective procedure to combat obesity in adolescents,// according to a ... first study to evaluate the lap band in patients under ... average lost about 50% of their excess weight by one ... issue of the Journal of Pediatric Surgery. Currently, the lap ...
... Women with a history of abuse by intimate partners ... women with no history of such abuse, according to ... plan. ,The higher costs and utilization continued ... Group Health, the University of Washington (UW), and the ...
Cached Medicine News:Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 3Health News:TEMPE Spray Delays Ejaculation 2Health News:Karnataka's Free Health Insurance to the Poor 2Health News:Transdermal Vaccine Effective in Treating Alzheimer's Disease in Mice 2Health News:Stomach Banding Surgery Effective for Adolescents 2Health News:Stomach Banding Surgery Effective for Adolescents 3Health News:Health Care Costs - Significant for Abused Women 2
Subretinal Fluid Cannula, Straight; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Lacrimal Cannula, Curved - Open End, 21gSize: 21g x 1-1/2"....
Medicine Products: